1. Introduction
===============

Recently, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported from Wuhan, China and has been rapidly spreading around the world. The coronavirus disease 2019 (COVID-19) is a newly identified infectious disease with the capacity for rapid human-to-human transmission and varied fatality due to acute respiratory distress syndrome (ARDS), multi-organ failure, and other serious complications (Huang et al., [@B4]; Zhu et al., [@B15]). By Dec. 8, 2019, several cases in Wuhan, China had been reported with most patients working at or living around the local Huanan Seafood Wholesale Market (Chen et al., [@B1]). After Dec. 8, the number of patients increased rapidly, although many patients had not been in or near the Huanan Seafood Wholesale Market. During the same period of time, many Wuhan residents began leaving the city to return to their hometowns to join with family to celebrate Spring Festival, the Chinese New Year. As a result of the overlap of emergence of the infection and surge of travel during the national holiday season, the COVID-19 disease began to spread quickly across China (Wu et al., [@B11]). Recognizing the problem, the Chinese government quickly took extreme measures to contain the spread of the virus, actions that included quarantining the entire city of Wuhan. Despite these efforts, however, the number of patients with COVID-19 rapidly increased. By Feb. 7, 2020, China had 31 161 patients diagnosed as COVID-19, with a large portion (22 112 cases) in Hubei Province with about half of those cases in the city of Wuhan (11 618 cases).

The epidemic situation in Zhejiang Province was relatively serious because many people from Wuhan returned to family homes within Zhejiang Province. The first case of COVID-19 in Zhejiang Province was diagnosed on Jan. 17, with the number of infections rapidly increasing after that date. Initially, these diagnosed patients were identified as having come from Wuhan. However, by Jan. 21, the first case of COVID-19 without Wuhan exposure was confirmed. Since then, the number of patients without Wuhan exposure gradually increased. At this time, very little was known about possible changes of epidemiological and clinical characteristics of the virus during human-to-human transmission.

SARS-CoV-2, influenza A, and other influenza viruses are single-stranded RNA viruses with a capsule envelope. These viruses cause upper respiratory tract infections and pneumonia in humans and are rapidly transmitted from person to person. For example, another influenza, pandemic type A (H1N1), arose in early 2009 (probably in Mexico and the United States) and then reappeared in North America in September over a 7-month period. H1N1 kept mutating during human-to-human transmission, causing continuous severe disease and mortality (Deng et al., [@B2]; Vazquez-Perez et al., [@B7]). Researchers found that adaptive mutations in H1N1 influenza virus in humans during the 2009 pandemic enhanced the virulence of the virus when studied in mice (Xu et al., [@B13]; Otte et al., [@B6]). However, researchers currently do not know if the virulence and pathogenicity of the SARS-CoV-2 virus increases or decreases during human-to-human transmission.

In this study, we analyze information on differences in epidemiological and clinical characteristics of COVID-19 patients, including those with and without a history of exposure to the virus in Wuhan. In addition to striving to better understand these characteristics, our goal was to investigate whether or not the virulence and pathogenicity of the SARS-CoV-2 virus was enhanced or decreased during human-to-human transmission.

2. Methods
==========

2.1. Data sources and ethics
----------------------------

We began a retrospective study focusing on the epidemiological and clinical characteristics of confirmed cases of COVID-19 from Jan. 17 to Feb. 7, 2020. All cases enrolled were quantitative real-time polymerase chain reaction (qRT-PCR)-positive for SARS-CoV-2 and were retested several times during their hospital stays. The data were collected uniformly by the Health Commission of Zhejiang Province (China), where all patients were assigned to specific hospitals for unified treatment according to Zhejiang Province's emergency rule. The diagnosis of COVID-19 infection was based on World Health Organization (WHO) interim guidance and all data were shared with WHO (WHO, [@B9]), with the primary analytic results reported to the authority of Zhejiang Province, China. Since the collection and analysis of all cases were determined by the Health Commission of Zhejiang Province under national authorization and considered as part of the continuing public health outbreak investigation, our study was exempt from institutional review board approval.

For further analysis, patients were divided into two groups indicating whether a patient had or did not have Wuhan exposure within one month. Patients with a history of Wuhan exposure were assigned to the "exposure group," and patients without Wuhan exposure history were assigned to the "control group." The subtype definition of COVID-19 patients was based on the diagnosis and treatment scheme for COVID-19 in China based on minor modification of WHO standards (Wu and McGoogan, [@B12]). The degree of COVID-19 was categorized as mild, severe, or critical: mild type included non-pneumonia and mild pneumonia cases; severe type was characterized by dyspnea, respiratory frequency of ≥30 min, blood oxygen saturation of ≤93%, PaO~2~/FiO~2~ ratio of \<300, and/or lung infiltrates of \>50% within 24--48 h; critical cases were those that exhibited respiratory failure, septic shock, and/or multiple organ dysfunction/failure.

2.2. Procedures
---------------

We obtained epidemiological, demographic, clinical, laboratory, management, and outcome data from patients' medical records. Data were retrieved and reviewed by two independent observers. Clinical outcomes were followed up to Feb. 12, 2020. Missing or vague dates were confirmed by direct communication with health care providers. Throat-swab specimens from upper respiratory tract and sputum from all patients were collected on admission and transported in a sputum cup with a tightly closed lid. Nasopharyngeal swab samples were transported in preservation tubes containing the virus preservation solution. Laboratory confirmation of COVID-19 was done in the First Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China) and other hospitals were under the authorization of the Center for Disease Control and Prevention (CDC) at the Zhejiang Province, by previously reported qRT-PCR methods. All patients were given chest X-rays or chest computed tomography (CT) scan at admission. Patients with other common respiratory viruses, including influenza A and B viruses, respiratory syncytial virus, parainfluenza virus, and adenovirus, were excluded from this study.

2.3. Outcomes
-------------

In this study, we collected and calculated epidemiological data including Wuhan exposure, by contacting confirmed patients and people in family clusters. We calculated the incubation period as being from the specific date of a person having contact with a confirmed COVID-19 patient to the date of illness onset. Other information collected included other anthropometrics, demographics, symptoms and signs of the patient at the time of admission to hospital. Additional data collected included results from laboratory tests and chest X-ray/CT scans, comorbidity, co-infection with other respiratory pathogen treatments (including drugs, intensive care, and mechanical ventilation), and other clinical outcomes.

2.4. Statistical analysis
-------------------------

For continuous variables, mean±standard deviation (SD) and median (interquartile range, IQR) were used for normally and abnormally distributed data, respectively, followed by un-paired *t* test and non-parametric test when applicable. Categorical variables were expressed as number (percentage) and compared by *χ^2^* test. A two-sided *α* of less than 0.05 was considered statistically significant and SPSS (IBM SPSS Statistics 26.0) was used for all analyses.

3. Results
==========

3.1. Demographic and epidemiologic characteristics
--------------------------------------------------

In this study, a total of 788 patients with confirmed COVID-19 were enrolled from Jan. 17, 2020 to Feb. 7, 2020 in Zhejiang Province. Clinical outcomes were followed-up through Feb. 12, 2020. As shown in Table [1](#T1){ref-type="table"}, there were 393 patients with, and 395 without a history of Wuhan exposure, with corresponding ages of (43.47±13.12) years and (48.19±16.13) years (*P*\<0.001). Patients in the control group were on average older than those in the exposure group. The number of patients aged 15--49 years in the exposure group is significantly higher than that in the control group (68.19% vs. 52.41%, *P*\<0.001). However, the number of patients aged over 65 years in the control group is significantly higher than that in the exposure group (15.95% vs. 5.60%, *P*\<0.001). There were no significant differences in the percentage of current smokers nor in percentage of women patients between the two groups. In addition, there were no significant differences in the presence of any coexisting medical conditions between the two groups, including rates of hypertension, diabetes, chronic liver disease, heart diseases, cancer, asthma, immunosuppression, chronic renal disease, and chronic obstructive pulmonary disease (COPD).

###### 

Demographic and epidemiologic characteristics of 788 COVID-19-infected patients with and without Wuhan exposure history

  Characteristics          Exposure group (*n*=393)   Control group (*n*=395)   *P* value
  ------------------------ -------------------------- ------------------------- -----------
  Age (year)               43.47±13.12                48.19±16.13               \<0.001
  Age group                                                                     
   0--14 years             7 (1.78%)                  9 (2.28%)                 0.802
   15--49 years            268 (68.19%)               207 (52.41%)              \<0.001
   50--64 years            96 (24.42%)                116 (29.36%)              0.127
   ≥65 years               22 (5.60%)                 63 (15.95%)               \<0.001
  Male sex                 216 (54.96%)               191 (48.35%)              0.064
  Current smoker           29 (7.34%)                 25 (6.33%)                0.576
  Coexisting condition                                                          
   Any                     108 (27.48%)               110 (27.85%)              0.937
   Hypertension            66 (16.79%)                60 (15.19%)               0.561
   Diabetes                23 (5.85%)                 34 (8.61%)                0.169
   Chronic liver disease   14 (3.56%)                 17 (4.30%)                0.715
   Cancer                  3 (0.76%)                  3 (0.76%)                 1.000
   Chronic renal disease   4 (0.51%)                  3 (0.76%)                 0.725
   Heart disease           3 (0.76%)                  8 (2.03%)                 0.223
   COPD                    1 (0.25%)                  2 (0.51%)                 1.000
   Asthma                  5 (1.27%)                  1 (0.25%)                 0.123
   Immunosuppression       0 (0.00%)                  1 (0.25%)                 1.000
  Family cluster           71 (18.66%)                124 (31.39%)              \<0.001
  Onset of symptom to                                                           
   Outpatient clinic (d)   2 (1.0--3.5)               2 (1.0--5.0)              0.019
   PCR confirmation (d)    4 (2.0--6.5)               5 (3.0--7.0)              0.009
   Admission (d)           3 (1.0--5.0)               4 (2.0--7.0)              \<0.001
  Severity on admission                                                         
   Mild                    354 (90.08%)               356 (90.13%)              1.000
   Severe                  31 (7.89%)                 30 (7.59%)                0.895
   Critical                8 (2.04%)                  9 (2.28%)                 1.000

Patients with Wuhan exposure history as "exposure group," and patients without Wuhan exposure history as "control group." Data are presented as mean±standard deviation (SD), number (percentage), or median (interquartile range, IQR). COPD: chronic obstructive pulmonary disease; PCR: polymerase chain reaction

The control group had a higher proportion of patients that had higher clustered onset than the exposure group (31.39% vs. 18.66%, *P*\<0.001). Since early patients were not screened in Wuhan, it is difficult to determine the specific date of contact with a confirmed COVID-19 patient; therefore, the incubation period could not be calculated for these patients. A total of 188 patients in the control group had a specific date of contact with confirmed COVID-19 patients and their calculated incubation period was 5 d (IQR: 3--9 d; range: 1--16 d). As shown in Fig. [1](#F1){ref-type="fig"}, from the first case of COVID-19 diagnosed in Zhejiang Province on Jan. 17, the number of patients with exposure history of Wuhan gradually increased. By Jan. 21, the first case of COVID-19 without Wuhan exposure was confirmed and the number reached a peak by Jan. 28. After that date, the number of patients without Wuhan exposure history exceeded that of patients with Wuhan exposure history. After the strong epidemic prevention and control measures initiated by the Zhejiang government by Jan. 28, the epidemic began coming under control as evidenced by the concurrently decreasing number of cases. There was no COVID-19 patient with Wuhan exposure history after Feb. 7. Our results showed that most patients' incubation time of COVID-19 was within two weeks.

![Onset of illness among 788 cases of COVID-19 in Zhejiang Province, China\
Patients with Wuhan exposure history as "exposure group," and patients without Wuhan exposure history as "control group"](JZUSB21-0369-fig01){#F1}

Because the COVID-19 outbreak began in Wuhan, the epidemiological history of patients was more complete in the exposure group than in the control group. In the exposure group, the time from onset of symptom to outpatient visit, qRT-PCR positive for SARS-CoV-2, and admission was shorter than that in the control group (*P*\<0.05), with no significant differences in the degree of COVID-19 symptoms recorded (mild, severe, or critical).

3.2. Clinical features and laboratory abnormalities
---------------------------------------------------

Table [2](#T2){ref-type="table"} shows the clinical characteristics of the patients. Fever (80.71%) and cough (64.21%) were the most common symptoms, followed by sputum production (33.63%), fatigue (17.64%), muscle ache (11.55%), gastrointestinal symptoms (11.17%), nasal obstruction (5.96%), shortness of breath (4.70%), and hemoptysis (1.90%). There were no significant differences among those symptoms between patients in the exposure and control groups. However and importantly, the presence of a sore throat in the exposure group was significantly higher than that in the control group (17.30% vs. 10.89%, *P*=0.01). The percentage of the symptom of headaches in the exposure group was significantly lower than that in the control group (6.87% vs. 12.15%, *P*=0.015).

###### 

Radiographic and laboratory findings of 788 COVID-19-infected patients with and without Wuhan exposure history

  Characteristics                                                        Exposure group (*n*=393)   Control group (*n*=395)   *P* value
  ---------------------------------------------------------------------- -------------------------- ------------------------- -----------
  Fever                                                                  320 (81.42%)               316 (80.00%)              0.652
  Cough                                                                  261 (66.41%)               245 (62.03%)              0.207
  Sputum production                                                      134 (34.10%)               131 (33.16%)              0.821
  Hemoptysis                                                             6 (1.53%)                  9 (2.28%)                 0.604
  Sore throat                                                            68 (17.30%)                43 (10.89%)               0.010
  Nasal obstruction                                                      27 (6.87%)                 20 (5.06%)                0.297
  Muscle ache                                                            42 (10.69%)                49 (12.41%)               0.504
  Fatigue                                                                67 (17.05%)                72 (18.23%)               0.709
  Shortness of breath                                                    17 (4.33%)                 20 (5.06%)                0.737
  GI symptoms                                                            36 (9.16%)                 52 (13.16%)               0.089
  Headache                                                               27 (6.87%)                 48 (12.15%)               0.015
  Blood routine                                                                                                               
   Leucocyte (×10^9^ L^−1^; normal range: 4--10)                         4.8 (3.8--6.0)             4.8 (3.8--6.0)            0.945
   \>10×10^9^ L^−1^                                                      11 (2.80%)                 7 (1.77%)                 0.353
   \<4×10^9^ L^−1^                                                       113 (28.75%)               121 (30.63%)              0.586
   Neutrophil (×10^9^ L^−1^; normal range: 2--7)                         2.96 (2.19--4.10)          2.95 (2.32--3.90)         0.517
   Lymphocyte (×10^9^ L^−1^; normal range: 0.8--4.0)                     1.2 (0.9--1.6)             1.2 (0.9--1.5)            0.676
   \<0.8×10^9^ L^−1^                                                     67 (17.05%)                67 (16.96%)               1.000
   ≥0.8×10^9^ L^−1^                                                      326 (82.95%)               328 (83.04%)              1.000
   Platelet (×10^9^ L^−1^; normal range: 83--303)                        183 (147--224)             178 (148--217)            0.487
   \<100×10^9^ L^−1^                                                     12 (3.05%)                 15 (3.80%)                0.696
   ≥100×10^9^ L^−1^                                                      381 (96.95%)               380 (96.20%)              0.696
   Hemoglobin (g/L; normal range: male 131--172, female 113--151)        139 (127--151)             137 (127--150)            0.579
   Hematokrit (%; normal range: male 38.0--50.8, female 33.5--45.0)      40.6 (37.6--44.3)          40.2 (37.8--43.7)         0.651
  Coagulation function                                                                                                        
   International normalized ratio (normal range: 0.85--1.15)             1.01 (0.97--1.08)          1.03 (0.97--1.10)         0.180
  Blood biochemistry                                                                                                          
   Albumin (g/L; normal range: 40--55)                                   41.42 (38.60--43.80)       41.40 (38.14--43.80)      0.582
   Alanine aminotransferase (U/L; normal range: 9--50)                   21.0 (15.0--32.0)          22.0 (15.0--35.0)         0.080
   Aspartate aminotransferase (U/L; normal range: 15--40)                24.0 (19.0--31.2)          27.0 (20.0--35.0)         0.001
   Total bilirubin (μmol/L; normal range: 0--26)                         9.75 (7.18--12.92)         9.40 (7.00--13.85)        0.789
   Serum sodium (mmol/L; normal range: 137--147)                         138.5 (136.7--140.1)       138.3 (136.0--140.1)      0.379
   Serum potassium (mmol/L; normal range: 3.5--5.3)                      3.82 (3.59--4.08)          3.87 (3.60--4.20)         0.222
   Blood urea nitrogen (mmol/L; normal range: 3.1--8.0)                  3.80 (3.05--4.59)          3.74 (3.00--4.70)         0.968
   Serum creatinine (μmol/L; normal range: male 57--97, female 41--73)   66.0 (55.0--78.0)          66.0 (56.0--77.0)         0.937
   Creatine kinase (U/L; normal range: 50--310)                          68.0 (55.0--78.0)          69.0 (46.6--112.5)        0.860
   Lactate dehydrogenase (U/L; normal range: 120--250)                   204.0 (165.0--254.0)       222.0 (173.0--296.0)      0.001
  Infection-related biomarker                                                                                                 
   C-reactive protein (mg/L; normal range: 0--8)                         7.8 (2.4--21.5)            8.2 (3.5--23.5)           0.325
   Procalcitonin (ng/mL; normal range: 0.0--0.5)                         0.05 (0.03--0.07)          0.05 (0.02--0.08)         0.132
  Chest X-ray/CT finding                                                                                                      
   Normal                                                                47 (11.96%)                40 (10.13%)               0.428
   Unilateral pneumonia                                                  85 (21.63%)                79 (20.00%)               0.599
   Bilateral pneumonia                                                   141 (35.88%)               155 (39.24%)              0.340
   Multiple mottling and ground-glass opacity                            120 (30.53%)               115 (29.11%)              0.697

Data are presented as number (percentage) or median (interquartile range, IQR). GI: gastrointestinal; CT: computed tomography

On admission, patients in the exposure group had significantly lower levels of lactate dehydrogenase (LDH; exposure group vs. control group, 204 U/L vs. 222 U/L; *P*=0.001) and aspartate aminotransferase (AST; exposure group vs. control group, 24 U/L vs. 27 U/L; *P*=0.001). There were no significant differences in the leucocytes, neutrophils, lymphocytes, platelets, hemoglobin, hematokrit, international normalized ratio, albumin, aminotransferase, bilirubin, serum sodium, serum potassium, blood urea nitrogen, serum creatinine, creatine kinase, C-reactive protein, or procalcitonin between the two groups. CT scan data are critical for disease identification and diagnosis and for all patients in the study there were no significant differences between the two groups of those with normal, unilateral pneumonia, bilateral pneumonia, or multiple mottling and ground-glass opacity.

3.3. Treatment and outcomes
---------------------------

All patients were isolated in designated hospitals and had supportive, needed, and currently recommended medication. Most patients (84.77%) received some forms of antiviral treatment including interferon-α sprays, arbidol hydrochloride capsules (100 mg po tid), and lopinavir and ritonavir tablets (500 mg po bid) (Table [3](#T3){ref-type="table"}). More patients in the exposure group received interferon-α and lopinavir/ritonavir combined therapy than those in the control group (24.43% vs. 17.47%, *P*=0.001). More patients in the control group than in the exposure group received a combined therapy of interferon-α, lopinavir/ritonavir, and arbidol (35.70% vs. 23.92%, *P*\<0.001). Patients in the exposure group received earlier antiviral treatment than those in the control group. The time from onset of illness to antiviral therapy was shorter in the exposure group than in the control group (3 d vs. 4 d, *P*\<0.001). There were no significant differences in the number of patients receiving glucocorticoid therapy between the two groups.

###### 

Complications, treatments, and outcomes in patients with and without Wuhan exposure history

  Variable                                                 Exposure group (*n*=393)   Control group (*n*=395)   *P* value
  -------------------------------------------------------- -------------------------- ------------------------- -----------
  Complication                                                                                                  
   Acute respiratory distress syndrome                     31 (7.89%)                 27 (6.84%)                0.588
   Septic shock                                            1 (0.25%)                  1 (0.25%)                 1.000
   Liver function abnormality                              39 (9.92%)                 43 (10.89%)               0.727
   Acute kidney injury                                     6 (1.53%)                  7 (1.77%)                 1.000
  Treatment                                                                                                     
   Anti-coronavirus treatment                              326 (82.95%)               342 (86.58%)              0.166
   Timing from onset of illness to antiviral therapy (d)   3 (1--5)                   4 (1--7)                  \<0.001
   Antivirus regimen                                                                                            
    Interferon-α+lopinavir/ritonavir+arbidol               94 (23.92%)                141 (35.70%)              \<0.001
    Interferon-α+lopinavir/ritonavir                       96 (24.43%)                69 (17.47%)               0.007
    Lopinavir/ritonavir+arbidol                            38 (9.67%)                 35 (8.86%)                0.620
    Lopinavir/ritonavir                                    35 (8.91%)                 33 (8.35%)                0.702
    Other                                                  63 (16.03%)                64 (16.20%)               0.844
   Mechanical ventilation                                  6 (1.53%)                  12 (3.04%)                0.232
   Non-invasive                                            5 (1.27%)                  2 (0.51%)                 0.286
   Invasive                                                1 (0.25%)                  10 (2.53%)                0.011
   CRRT                                                    0 (0.00%)                  0 (0.00%)                 
   ECMO                                                    0 (0.00%)                  0 (0.00%)                 
   Glucocorticoids                                         56 (14.25%)                44 (11.14%)               0.200
   Maximum dosage (mg)[\*](#T3FN1){ref-type="fn"}          40 (40--80)                40 (40--80)               0.953
   IVIG                                                    35 (8.91%)                 27 (6.84%)                0.293
   Admission to intensive care unit                        5 (1.27%)                  17 (4.30%)                0.015
  Discharged from hospital                                 210 (53.44%)               112 (28.35%)              \<0.001

Glucocorticoid dosages were converted into an equivalent of methylprednisolone. Data are presented as number (percentage) or median (interquartile range, IQR). CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; IVIG: intravenous immunoglobulin

In this study, 1.53% patients in the exposure group received mechanical ventilation while 3.04% patients in the control group were ventilated (*P*=0.232). The ventilator adopted pressure-controlled synchronized intermittent mandatory ventilation (P-SIMV) mode, with the inhaled oxygen concentration of 35%--100% and the positive end-expiratory pressure of 6--12 cmH~2~O (1 cmH~2~O=98.06 Pa). However, significantly fewer patients in the exposure group were admitted into intensive care unit (ICU) than those in the control group (1.27% vs. 4.30%, *P*=0.015) by Feb. 12, 2020. At present, we are aware of no patients who have received continuous blood purification due to renal failure and extracorporeal membrane oxygenation (ECMO) in the two groups. Liver injury was the most common complication, followed by ARDS and acute kidney injury, but the differences of these complications were not statistically significant between the two groups. By the end of Feb. 12, all patients had survived and patients in the exposure group had significantly higher rate of hospital discharge than those in the control group (53.44% vs. 28.35%, *P*\<0.001).

4. Discussion
=============

As previously noted, an outbreak of a novel coronavirus (SARS-CoV-2) was first recorded in Wuhan, China in Dec. 2019, and soon spread to other parts of the world. Because of the high transmissibility of the virus, WHO classified this situation as a public health emergency of international concern (PHEIC) (Li et al., [@B5]; Zhu et al., [@B15]). On Jan. 23, 2020, China quarantined the entire city of Wuhan to contain the spread of COVID-19. Although the Chinese government made great efforts to control the spread of the epidemic, the epidemic continued to spread nationwide.

Viral mutation can occur over successive human-to-human transmissions, increasing the probability of adaptation to human hosts during a pandemic outbreak and as a virus mutates, its virulence and pathogenicity may either increase or decrease (Wong et al., [@B10]). One example of this is pandemic type A (H1N1) influenza which appeared in early 2009 and, as previously noted, reappeared in North America in September. Researchers have reported that an amino acid substitution in the hemagglutinin (HA), D222G, was present in a significant proportion of patients with a severe and fatal outcome. Mutations in HA, non-structural protein 1 (NS1), and polymerase basic protein 2 (PB2) of influenza viruses have been associated with virulence during virus passage (Goka et al., [@B3]).

The data from Wuhan revealed high mortality of COVID-19. Chen et al. ([@B1]) showed that 11 (11%) of 99 patients who contracted the disease worsened in a short period of time and died of multiple organ failure. Another study from Wuhan showed that among 138 hospitalized patients with confirmed COVID-19, 26% received ICU care with a mortality rate of 4.3% (Wang et al., [@B8]). In a study by Yang et al. ([@B14]) the mortality rate for critically ill patients exceeded 60%. The Chinese CDC recently published the largest case series to date of COVID-19 in mainland China (72 314 cases, updated through Feb. 11, [@B12]), where the fatality rate was 2.3% (1023 of 44 672 confirmed cases) (Wu and McGoogan, [@B12]). At this time, the overall national mortality rate in China has been lower than that in Wuhan City.

Our study showed that the number of patients aged over 65 years in the control (non-exposed) group is significantly higher than that in the exposure group, but there was no significant difference in the degree of illness (mild, severe, or critical) between the two groups. We compared the proportion of severe/critical type in younger (\<60 years) between these two groups and found no significant difference. We also compared radiographic and laboratory findings of 788 COVID-19 patients with and without exposure to Wuhan, where only the differences in AST and LDH were statistically significant between the two groups. The differences in AST and LDH may be due to age differences between the groups since patients in the control group were older than those in the exposure group. Patients from Wuhan were diagnosed earlier because of a clear epidemiological history. In addition, patients with early onset had a history of Wuhan exposure and had a higher discharge rate. Therefore, from the perspective of epidemiological and clinical characteristics, no significant differences were found between COVD-19 patients with and without Wuhan exposure. The mortality rate of COVID-19 patients across the full range of Zhejiang Province is significantly lower than those directly in the city of Wuhan. The differences in mortality may be due to the early diagnosis and treatment of COVID-19 patients in Zhejiang Province, and the ICU-level care may be more readily available in Zhejiang Province, contributing to the improved survival.

Our study has several limitations. First, the retrospective nature of this study may decrease its accuracy; a future cohort study could confirm our findings. Second, we compared groups only from the perspective of epidemiological and clinical characteristics without direct virologic evidence which would have provided more direct and reliable data. Third, the data regarding the outcomes of patients with COVID-19 need to be further investigated, as at the time of this study most patients were still under treatment in hospital.
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